Financial Performance - Total revenue for Q3 2023 was CNY 151,979,404.68, a decrease of 4.66% compared to the same period last year[5]. - Net profit attributable to shareholders was CNY -15,311,739.16, down 30.48% year-on-year[5]. - The net profit for Q3 2023 was -29,616,167.81 CNY, compared to a net profit of 24,700,043.00 CNY in the same period last year, indicating a significant decline[24]. - The operating profit for Q3 2023 was -43,073,876.78 CNY, a decrease from an operating profit of 21,733,340.43 CNY in Q3 2022[24]. - Total comprehensive income for Q3 2023 was -29,616,167.81 CNY, down from 24,700,043.00 CNY in Q3 2022[24]. - Basic and diluted earnings per share for Q3 2023 were both -0.21 CNY, compared to 0.15 CNY in the same quarter last year[24]. Cash Flow and Investments - Cash flow from operating activities showed a net outflow of CNY -43,779,885.16, a significant decline of 883.59%[5]. - Cash flow from operating activities showed a net outflow of -43,779,885.16 CNY, compared to a net inflow of 5,587,061.30 CNY in the previous year[25]. - The company reported cash inflows from investment activities of 1,094,330,476.44 CNY, compared to 1,021,390,391.30 CNY in the previous year[25]. - Cash outflows from investment activities were 1,579,215,704.55 CNY, significantly higher than 863,926,969.04 CNY in the same period last year[25]. - The net cash flow from financing activities was 262,937,916.17 CNY, compared to a net outflow of -5,963,076.52 CNY in Q3 2022[25]. Assets and Liabilities - Total assets at the end of the reporting period reached CNY 2,926,873,859.69, an increase of 8.15% from the end of the previous year[5]. - The total liabilities decreased to ¥332,725,788.51 from ¥371,203,811.43, showing a reduction of about 10.3%[20]. - The company's equity attributable to shareholders increased by 11.35% to CNY 2,572,538,619.15 compared to the end of last year[5]. - The company's equity attributable to shareholders increased to ¥2,572,538,619.15 from ¥2,310,371,030.54, marking an increase of approximately 11.36%[20]. Expenses - Operating expenses saw a dramatic rise of 697.99%, totaling CNY 6,220,852.65, primarily due to increased losses from fixed asset disposals[10]. - The income tax expense increased by 453.74%, amounting to CNY -19,556,716.17, mainly due to a decrease in profits during the reporting period[10]. - Research and development expenses for the third quarter were ¥90,738,631.99, up from ¥85,474,972.58, reflecting an increase of about 6.5%[21]. Other Financial Metrics - The company reported a 220.14% increase in development expenditures, totaling CNY 3,224,400.00, due to increased capitalized R&D investments[9]. - Financial expenses decreased by 34.95% to CNY -5,745,925.22, primarily due to increased interest expenses being capitalized[9]. - The company experienced a 9122.68% increase in credit impairment losses, amounting to CNY 2,161,118.71, attributed to changes in accounts receivable aging[9]. - The company reported a significant increase of 358.71% in trading financial assets, totaling CNY 660,739,720.61, due to increased investment in financial products[9]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,485, with no preferred shareholders[12]. Financing Activities - The company received CNY 289,999,984.56 from investment financing, marking a 100% increase due to funds raised from stock issuance[10]. - Cash received from bank loans was CNY 10,000,000.00, representing a 100% increase as a result of obtaining bank loans during the reporting period[10]. - The company reported a 34.66% decrease in cash paid for dividends and interest, totaling CNY 583,625.00, due to reduced bank loan interest payments[10].
海特生物(300683) - 2023 Q3 - 季度财报